Preliminary evidence for association between schizophrenia and polymorphisms in the regulatory Regions of the ADRA2A, DRD3 and SNAP-25 Genes

Psychiatry Research

Volumn 205, Issue 1-2, 2013, Pages 7-12

  Lochman, Jan ^a   Balcar, Vladimir J ^c   Šťastný, František ^a   Šerý, Omar ^b  

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF SYDNEY   (Australia)

^c INSTITUTE OF ANIMAL PHYSIOLOGY AND GENETICS   (Czech Republic)

Author keywords

Adrenergic receptor; Association; Dopamine receptor; Schizophrenia

Indexed keywords

ALPHA 2A ADRENERGIC RECEPTOR; DOPAMINE 1 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE BETA MONOOXYGENASE; SYNAPTOSOMAL ASSOCIATED PROTEIN 25;

ADULT; ALPHA 2A ADRENERGIC RECEPTOR GENE; ARTICLE; CONTROLLED STUDY; DOPAMINE BETA HYDROXYLASE GENE; DOPAMINE RECEPTOR D3 GENE; DOPAMINERGIC SYSTEM; GENE INTERACTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SYNAPTOSOMAL ASSOCIATED PROTEIN 25 GENE;

ADULT; CASE-CONTROL STUDIES; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LIKELIHOOD FUNCTIONS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, DOPAMINE D3; SCHIZOPHRENIA; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25;

EID: 84872600527     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2012.08.003     Document Type: Article

References (49)

1. Aleman A., Kahn R.S., Selten J.P. Sex differences in the risk of schizophrenia: evidence from meta-analysis. Archives of General Psychiatry 2003, 60:565-571.
2. Bartzokis G., Lu P.H., Stewart S.B., Oluwadara B., Lucas A.J., Pantages J., Pratt E., Sherin J.E., Altshuler L.L., Mintz J., Mintz J., Gitlin M.J., Subotnik K.L., Nuechterlein K.H. In vivo evidence of differential impact of typical and atypical antipsychotics on intracortical myelin in adults with schizophrenia. Schizophrenia Research 2009, 113:322-331.
3. Bolonna A.A., Arranz M.J., Munro J., Osborne S., Petouni M., Martinez M., Kerwin R.W. No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response. Neuroscience Letters 2000, 280:65-68.
4. Bombin I., Arango C., Mayoral M., Castro-Fornieles J., Gonzalez-Pinto A., Gonzalez-Gomez C., Moreno D., Parellada M., Baeza I., Graell M., Otero S., Saiz P.A., Patiño-Garcia A. DRD3, but not COMT or DRD2, genotype affects executive functions in healthy and first-episode psychosis adolescents. American Journal of Medical Genetics Part B-Neuropsychiatric Genetics 2008, 147B:873-879.
5. Bongarzone E.R., Howard S.G., Schonmann V., Campagnoni A.T. Identification of the dopamine D3 receptor in oligodendrocyte precursors: potential role in regulating differentiation and myelin formation. Journal of Neuroscience 1998, 18:5344-5353.
6. Carroll L.S., Kendall K., O'Donovan M.C., Owen M.J., Williams N.M. Evidence that putative ADHD low risk alleles at SNAP25 may increase the risk of schizophrenia. American Journal of Medical Genetics Part B-Neuropsychiatric Genetics 2009, 150B:893-899.
7. Clark D.A., Arranz M.J., Mata I., Lopez-Ilundain J., Perez-Nievas F., Kerwin R.W. Polymorphisms in the promoter region of the alpha1A-adrenoceptor gene are associated with schizophrenia/schizoaffective disorder in a Spanish isolate population. Biological Psychiatry 2005, 58:435-439.
8. Clark D.A., Mata I., Kerwin R.W., Munro J., Arranz M.J. No association between ADRA2A polymorphisms and schizophrenia. American Journal of Medical Genetics Part B-Neuropsychiatric Genetics 2007, 144B:341-343.
9. Comings D.E., Gonzalez N.S., Li C., MacMurray J. A "line item" approach to the identification of genes involved in polygenic behavioral disorders: the adrenergic alpha2A ADRA2A gene. American Journal of Medical Genetics Part B-Neuropsychiatric Genetics 2003, 118B:110-114.
10. Deupree J.D., Smith S.D., Kratochvil C.J., Bohac D., Ellis C.R., Polaha J., Bylund D.B. Possible involvement of alpha-2A adrenergic receptors in attention deficit hyperactivity disorder: Radioligand binding and polymorphism studies. American Journal of Medical Genetics Part B-Neuropsychiatric Genetics 2006, 141B:877-884.
11. Fanous A.H., Zhao Z., van den Oord E.J.C.G., Maher B.S., Thiselton D.L., Bergen S.E., Wormley B., Bigdeli T., Amdur R.L., O'Neill F.A., Walsh D., Kendler K.S., Riley B.P Association study of SNAP25 and schizophrenia in Irish family and case-control samples. American Journal of Medical Genetics Part B-Neuropsychiatric Genetics 2010, 153B:663-674.
12. Garcia-Sevilla J.A., Escriba P.V., Ozaita A., La Harpe R., Walzer C., Eytan A., Guimon J. Up-regulation of immunolabeled alpha2A-adrenoceptors, Gi coupling proteins, and regulatory receptor kinases in the prefrontal cortex of depressed suicides. Journal of Neurochemistry 1999, 72:282-291.
13. Hoistad M., Segal D., Takahashi N., Sakurai T., Buxbaum J.D., Hof P.R. Linking white and grey matter in schizophrenia: oligodendrocyte and neuron pathology in the prefrontal cortex. Frontiers in Neuroanatomy 2009, 3:9.
14. Honer W.G., Falkai P., Bayer T.A., Xie J., Hu L., Li H.Y., Arango V., Mann J.J., Dwork A.J., Trimble W.S. Abnormalities of SNARE mechanism proteins in anterior frontal cortex in severe mental illness. Cerebral Cortex 2002, 12:349-356.
15. Jeanneteau F., Funalot B., Jankovic J., Deng H., Lagarde J.P., Lucotte G., Sokoloff P. A functional variant of the dopamine D-3 receptor is associated with risk and age-at-onset of essential tremor. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:10753-10758.
16. Kim J.W., Biederman J., Arbeitman L., Fagerness J., Doyle A.E., Petty C., Perlis R.H., Purcell S., Smoller J.W., Faraone S.V., Sklar P. Investigation of variation in SNAP-25 and ADHD and relationship to co-morbid major depressive disorder. American Journal of Medical Genetics Part B-Neuropsychiatric Genetics 2007, 144B:781-790.
17. Koster A., Lajer M., Lindhardt A. Gender differences in patients with first episode psychosis. Acta Psychiatrica Scandinavica 2006, 114. 15-15.
18. Kumamoto N., Matsuzaki S., Inoue K., Hattori T., Shimizu S., Hashimoto R., Yamatodani A., Katayama T., Tohyama M. Hyperactivation of midbrain dopaminergic system in schizophrenia could be attributed to the down-regulation of dysbindin. Biochemical and Biophysical Research Communications 2006, 345:904-909.
19. Lau C.G., Takayasu Y., Rodenas-Ruano A., Paternain A.V., Lerma J., Bennett M.V.L., Zukin R.S. SNAP-25 is a target of protein kinase C phosphorylation critical to NMDA receptor trafficking. Journal of Neuroscience 2010, 30:242-254.
20. Lecrubier Y., Sheehan D.V., Weiller E., Amorim P., Bonora I., Sheehan K.H., Janavs J., Dunbar G.C. The Mini International Neuropsychiatric Interview MINI. A short diagnostic structured interview: reliability and validity according to the CIDI. European Psychiatry 1997, 12:224-231.
21. Lee S.H., Mouradian M.M. Up-regulation of D-1A dopamine receptor gene transcription by estrogen. Molecular and Cellular Endocrinology 1999, 156:151-157.
22. Leung A., Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatrica Scandinavica 2000, 101:3-38.
23. Lundstrom K., Turpin M.P. Proposed schizophrenia-related gene polymorphism: Expression of the Ser9Gly mutant human dopamine D-3 receptor with the Semliki Forest virus system. Biochemical and Biophysical Research Communications 1996, 225:1068-1072.
24. Lundstrom K., Turpin M.P., Large C., Robertson G., Thomas P., Lewell X.Q. Mapping of dopamine D-3 receptor binding site by pharmacological characterization of mutants expressed in CHO cells with the Semliki Forest virus system. Journal of Receptor and Signal Transduction Research 1998, 18. 133-+.
25. Ma G., He Z.D., Fang W.L., Tang W., Huang K., Li Z.Q., He G., Xu Y.F., Feng G.Y., Zheng T., et al. The Ser9Gly polymorphism of the dopamine D3 receptor gene and risk of schizophrenia: an association study and a large meta-analysis. Schizophrenia Research 2008, 101:26-35.
26. Maes M., Van Gastel A., Delmeire L., Meltzer H.Y. Decreased platelet alpha-2 adrenoceptor density in major depression: effects of tricyclic antidepressants and fluoxetine. Biological Psychiatry 1999, 45:278-284.
27. Marcus M.M., Wiker C., Franberg O., Konradsson-Geuken A., Langlois X., Jardemark K., Svensson T.H. Adjunctive alpha2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission. International Journal of Neuropsychopharmacology 2010, 13:891-903.
28. Mukaetova-Ladinska E.B., Hurt J., Honer W.G., Harrington C.R., Wischik C.M. Loss of synaptic but not cytoskeletal proteins in the cerebellum of chronic schizophrenics. Neuroscience Letters 2002, 317:161-165.
29. Nieoullon A. Dopamine and the regulation of cognition and attention. Progress in Neurobiology 2002, 67:53-83.
30. Nunokawa A., Watanabe Y., Kaneko N., Sugai T., Yazaki S., Arinami T., Ujike H., Inada T., Iwata N., Kunugi H., Sasaki T., Itokawa M., Ozaki N., Hashimoto R., Someya T. The dopamine D3 receptor (DRD3) gene and risk of schizophrenia: Case-control studies and an updated meta-analysis. Schizophrenia Research 2010, 116:61-67.
31. Ordway G.A., Schenk J., Stockmeier C.A., May W., Klimek V. Elevated agonist binding to alpha2-adrenoceptors in the locus coeruleus in major depression. Biological Psychiatry 2003, 53:315-323.
32. Sery O., Prikryl R., Castulik L., Stastny F. A118G Polymorphism of OPRM1 gene is associated with schizophrenia. Journal of Molecular Neuroscience 2010, 41:219-222.
33. Sullivan P.F. Spurious genetic associations. Biological Psychiatry 2007, 61:1121-1126.
34. Talkowski M.E., Bamne M., Mansour H., Nimgaonkar V.L. Dopamine genes and schizophrenia: case closed or evidence pending?. Schizophrenia Bulletin 2007, 33:1071-1081.
35. Talkowski M.E., Kirov G., Bamne M., Georgieva L., Torres G., Mansour H., Chowdari K.V., Milanova V., Wood J., McClain L., Prasad K., Shirts B., Zhang J., O'Donovan M.C., Owen M.J., Devlin B., Nimgaonkar V.L. A network of dopaminergic gene variations implicated as risk factors for schizophrenia. Human Molecular Genetics 2008, 17:747-758.
36. Tang Y.L., Buxbaum S.G., Waldman I., Anderson G.M., Zabetian C.P., Kohnke M.D., Cubells J.F. A single nucleotide polymorphism at DBH, possibly associated with attention-deficit/hyperactivity disorder, associates with lower plasma dopamine beta-hydroxylase activity and is in linkage disequilibrium with two putative functional single nucleotide polymorphisms. Biological Psychiatry 2006, 60:1034-1038.
37. Thompson P.M., Egbufoama S., Vawter M.P. SNAP-25 reduction in the hippocampus of patients with schizophrenia. Progress in Neuro-Psychopharmacology &. Biological Psychiatry 2003, 27:411-417.
38. Thompson P.M., Kelley M., Yao J., Tsai G.C., van Kammen D.P. Elevated cerebrospinal fluid SNAP-25 in schizophrenia. Biological Psychiatry 2003, 53:1132-1137.
39. Tsai S.J., Wang Y.C., Younger W.Y.Y., Lin C.H., Yang K.H., Hong C.J. Association analysis of polymorphism in the promoter region of the alpha 2a-adrenoceptor gene with schizophrenia and clozapine response. Schizophrenia Research 2001, 49:53-58.
40. Utsunomiya K., Shinkai T., De Lucac V., Hwangc R., Sakata S., Fukunaka Y., Chen H.I., Ohmori O., Nakamura J. Genetic association between the dopamine D3 gene polymorphism Ser9Gly and schizophrenia in Japanese populations: Evidence from a case-control study and meta-analysis. Neuroscience Letters 2008, 444:161-165.
41. Vostrikov V., Orlovskaya D., Uranova N. Deficit of pericapillary oligodendrocytes in the prefrontal cortex in schizophrenia. World Journal of Biological Psychiatry 2008, 9:34-42.
42. Vrajova M., Stastny F., Horacek J., Lochman J., Sery O., Pekova S., Klaschka J., Hoschl C. Expression of the hippocampal NMDA receptor GluN1 subunit and its splicing isoforms in schizophrenia: postmortem study. Neurochemical Research 2010, 35:994-1002.
43. Wang Y., Tang B.L. SNAREs in neurons - beyond synaptic vesicle exocytosis (review). Molecular Membrane Biology 2006, 23:377-384.
44. Williams N.M., O'Donovan M.C., Owen M.J. Is the dysbindin gene DTNBP1 a susceptibility gene for schizophrenia?. Schizophrenia Bulletin 2005, 31:800-805.
45. Yamamoto K., Hornykiewicz O. Proposal for a noradrenaline hypothesis of schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry 2004, 28:913-922.
46. Zhang C., Fang Y.R., Xie B., Cheng W.H., Du Y.S., Wang D.X., Yu S.Y. No genetic association between dopamine D1 receptor gene and [early onset] schizophrenia. Psychiatry Research 2010, 177:350-353.
47. Zhang F., Fan H., Xu Y., Zhang K., Huang X., Zhu Y., Sui M., Sun G., Feng K., Xu B., Zhang X., Su Z., Peng C., Liu P. Converging evidence implicates the dopamine D3 receptor gene in vulnerability to schizophrenia. American Journal of Medical Genetics Part B-Neuropsychiatric Genetics 2011, 156B:613-619.
48. Zhao J.H. 2LD, GENECOUNTING and HAP: computer programs for linkage disequilibrium analysis. Bioinformatics 2004, 20:1325-1326.
49. Zhu, F., Yan, C.X., Wang, Q., Zhu, Y.S., Zhao, Y., Huang, J., Zhang, H.B., Gao, C.G., Li, S.B., 2011. An association study between dopamine D1 receptor gene polymorphisms and the risk of schizophrenia. Brain Research 1420, 106-113.